Skip to main content

Table 1 Patient characteristics

From: Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis

  No Reaction Reaction  
  103 22  
Female 100 (97.1%) 18 (81.8%)  
Male 3 (2.91%) 4 (18.2%) 0.005**
Age at first dose of RTX 37 (16–73) 30 (18–56) 0.068
Cycles of RTX 1.91 (1–9) 2.18 (1–8) 0.202
ANA positive 90 (87.4%) 22 (100%) 0.066
dsDNA positive 65 (63.1%) 16 (72.7%) 0.972
No ENA pos 25 (24.3%) 6 (27.3%) 0.767
1 ENA pos 26 (25.2%) 5 (22.7%) 0.804
2 ENA pos 28 (27.2%) 8 (36.4%) 0.388
3 ENA pos 16 (15.5%) 2 (9.1%) 0.435
4 ENA pos 8 (7.8%) 1 (4.5%) 0.596
Anti-Ro positive 57 (55.3%) 12 (54.5%) 0.946
Anti-La positive 24 (23.3%) 2 (9.1%) 0.136
Anti-Sm positive 33 (32.0%) 5 (22.7%) 0.389
Anti-RNP positive 48 (46.6%) 12 (54.5%) 0.498
Caucasian 40 (38.8%) 9 (40.9%) 0.856
Afro-Caribbean 43 (41.7%) 10 (45.5%) 0.749
Asian 16 (15.5%) 2 (9.1%) 0.435
Other 4 (3.9%) 1 (4.5%) 0.886
  1. NB. “x ENA” refer’s to the number of antibodies to extractible nuclear antigen’s detectable in an individual patient